Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.

Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Östman A, Sier CFM, Prakash J.

Sci Adv. 2019 Sep 4;5(9):eaax2770. doi: 10.1126/sciadv.aax2770. eCollection 2019 Sep.

2.

A marker-independent lineage-tracing system to quantify clonal dynamics and stem cell functionality in cancer tissue.

Lenos KJ, Lodestijn SC, Lyons SK, Bijlsma MF, Miedema DM, Vermeulen L.

Nat Protoc. 2019 Sep;14(9):2648-2671. doi: 10.1038/s41596-019-0194-y. Epub 2019 Aug 16.

PMID:
31420599
3.

Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.

Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, Busch OR, van Delden OM, Halfwerk H, van Hooft JE, van Lienden KP, Marchegiani G, Meijer SL, van Noesel CJ, Reinten RJ, Roos E, Schokker S, Verheij J, van de Vijver MJ, Waasdorp C, Wilmink JW, Ylstra B, Besselink MG, Bijlsma MF, Dijk F, van Laarhoven HW.

Int J Cancer. 2019 Jul 24. doi: 10.1002/ijc.32586. [Epub ahead of print]

PMID:
31340061
4.

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).

Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM.

Cancers (Basel). 2019 Jun 14;11(6). pii: E827. doi: 10.3390/cancers11060827.

5.

Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment.

Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E.

Ther Adv Med Oncol. 2019 May 10;11:1758835919841233. doi: 10.1177/1758835919841233. eCollection 2019.

6.

Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis.

van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM.

Cancers (Basel). 2019 Apr 26;11(5). pii: E588. doi: 10.3390/cancers11050588. Review.

7.

Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.

Steins A, Ebbing EA, Creemers A, van der Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, van Delden OM, Krishnadath KK, Hulshof MCCM, Bennink RJ, Punt CJA, Medema JP, Bijlsma MF, van Laarhoven HWM.

Int J Cancer. 2019 Nov 15;145(10):2792-2803. doi: 10.1002/ijc.32364. Epub 2019 May 7.

8.

Smoothened-dependent and -independent pathways in mammalian noncanonical Hedgehog signaling.

Faria AVS, Akyala AI, Parikh K, Brüggemann LW, Spek CA, Cao W, Bruno MJ, Bijlsma MF, Fuhler GM, Peppelenbosch MP.

J Biol Chem. 2019 Jun 21;294(25):9787-9798. doi: 10.1074/jbc.RA119.007956. Epub 2019 Apr 16.

PMID:
30992365
9.

Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts.

van der Heijden M, Miedema DM, Waclaw B, Veenstra VL, Lecca MC, Nijman LE, van Dijk E, van Neerven SM, Lodestijn SC, Lenos KJ, de Groot NE, Prasetyanti PR, Arricibita Varea A, Winton DJ, Medema JP, Morrissey E, Ylstra B, Nowak MA, Bijlsma MF, Vermeulen L.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6140-6145. doi: 10.1073/pnas.1813417116. Epub 2019 Mar 8.

10.

Cancer stem cells: here, there, and everywhere.

Lodestijn SC, Lenos KJ, Miedema DM, Bijlsma MF, Vermeulen L.

Mol Cell Oncol. 2018 Dec 4;6(1):1540235. doi: 10.1080/23723556.2018.1540235. eCollection 2019.

PMID:
30788417
11.

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.

Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22.

12.

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.

Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF.

Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.

13.

Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice: comment.

Spek CA, Tekin C, Bijlsma MF.

J Thromb Haemost. 2019 Jan;17(1):235-238. doi: 10.1111/jth.14329. Epub 2018 Dec 4. No abstract available.

PMID:
30412650
14.

Multidrug-resistant transporter expression does not always result in drug resistance.

Le Large TYS, El Hassouni B, Kazemier G, Piersma SR, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E.

Cancer Sci. 2018 Oct;109(10):3360-3362. doi: 10.1111/cas.13756. Epub 2018 Sep 8. No abstract available.

15.

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Creemers A, Ebbing EA, Pelgrim TC, Lagarde SM, van Etten-Jamaludin FS, van Berge Henegouwen MI, Hulshof MCCM, Krishnadath KK, Meijer SL, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2018 Sep 5;8(1):13281. doi: 10.1038/s41598-018-31548-6.

16.

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.

Lenos KJ, Miedema DM, Lodestijn SC, Nijman LE, van den Bosch T, Romero Ros X, Lourenço FC, Lecca MC, van der Heijden M, van Neerven SM, van Oort A, Leveille N, Adam RS, de Sousa E Melo F, Otten J, Veerman P, Hypolite G, Koens L, Lyons SK, Stassi G, Winton DJ, Medema JP, Morrissey E, Bijlsma MF, Vermeulen L.

Nat Cell Biol. 2018 Oct;20(10):1193-1202. doi: 10.1038/s41556-018-0179-z. Epub 2018 Sep 3.

17.

PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.

Tekin C, Shi K, Daalhuisen JB, Ten Brink MS, Bijlsma MF, Spek CA.

Oncotarget. 2018 Aug 10;9(62):32010-32023. doi: 10.18632/oncotarget.25880. eCollection 2018 Aug 10.

18.

The dynamics of HER2 status in esophageal adenocarcinoma.

Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM.

Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1.

19.

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma.

Houg DS, Bijlsma MF.

Mol Cancer. 2018 Jun 14;17(1):95. doi: 10.1186/s12943-018-0842-9. Review.

20.

Patched-2 functions to limit Patched-1 deficient skin cancer growth.

Veenstra VL, Dingjan I, Waasdorp C, Damhofer H, van der Wal AC, van Laarhoven HW, Medema JP, Bijlsma MF.

Cell Oncol (Dordr). 2018 Aug;41(4):427-437. doi: 10.1007/s13402-018-0381-9. Epub 2018 Jun 4.

21.

Molecular subtyping of cancer: current status and moving toward clinical applications.

Zhao L, Lee VHF, Ng MK, Yan H, Bijlsma MF.

Brief Bioinform. 2019 Mar 25;20(2):572-584. doi: 10.1093/bib/bby026.

PMID:
29659698
22.

The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases.

Strijker M, Gerritsen A, van Hilst J, Bijlsma MF, Bonsing BA, Brosens LA, Bruno MJ, van Dam RM, Dijk F, van Eijck CH, Farina Sarasqueta A, Fockens P, Gerhards MF, Groot Koerkamp B, van der Harst E, de Hingh IH, van Hooft JE, Huysentruyt CJ, Kazemier G, Klaase JM, van Laarhoven CJ, van Laarhoven HW, Liem MS, de Meijer VE, van Rijssen LB, van Santvoort HC, Suker M, Verhagen JH, Verheij J, Verspaget HW, Wennink RA, Wilmink JW, Molenaar IQ, Boermeester MA, Busch OR, Besselink MG; Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group.

Pancreas. 2018 Apr;47(4):495-501. doi: 10.1097/MPA.0000000000001018.

PMID:
29521943
23.

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer.

Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF.

Cancers (Basel). 2018 Jan 27;10(2). pii: E34. doi: 10.3390/cancers10020034. Review.

24.

Epigenetic regulation of the Hedgehog and Wnt pathways in cancer.

Wils LJ, Bijlsma MF.

Crit Rev Oncol Hematol. 2018 Jan;121:23-44. doi: 10.1016/j.critrevonc.2017.11.013. Epub 2017 Nov 24. Review.

25.

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Steins A, Ebbing EA, Pistorius MCM, Waasdorp C, Krishnadath KK, Medema JP, Wilmink JW, Mathôt RAA, Bijlsma MF, van Laarhoven HWM.

Drug Deliv. 2017 Nov;24(1):1801-1810. doi: 10.1080/10717544.2017.1406559.

PMID:
29172757
26.

Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma.

Bijlsma MF, Roelink H.

J Invest Dermatol. 2017 Dec;137(12):2469-2471. doi: 10.1016/j.jid.2017.07.816.

27.

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review.

van der Horst A, Versteijne E, Besselink MGH, Daams JG, Bulle EB, Bijlsma MF, Wilmink JW, van Delden OM, van Hooft JE, Franken NAP, van Laarhoven HWM, Crezee J, van Tienhoven G.

Int J Hyperthermia. 2018 Nov;34(7):969-979. doi: 10.1080/02656736.2017.1401126. Epub 2017 Nov 23.

PMID:
29168401
28.

Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.

Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):394-403. doi: 10.1016/j.bbcan.2017.08.002. Epub 2017 Aug 8. Review.

PMID:
28801248
29.

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis.

Creemers A, Ter Veer E, de Waal L, Lodder P, Hooijer GKJ, van Grieken NCT, Bijlsma MF, Meijer SL, van Oijen MGH, van Laarhoven HWM.

Sci Rep. 2017 Jun 9;7(1):3135. doi: 10.1038/s41598-017-03304-9.

30.

Stromal SPOCK1 supports invasive pancreatic cancer growth.

Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, van Laarhoven HW, Bijlsma MF.

Mol Oncol. 2017 Aug;11(8):1050-1064. doi: 10.1002/1878-0261.12073. Epub 2017 Jun 5.

31.

Molecular subtypes in cancers of the gastrointestinal tract.

Bijlsma MF, Sadanandam A, Tan P, Vermeulen L.

Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):333-342. doi: 10.1038/nrgastro.2017.33. Epub 2017 Apr 12. Review.

PMID:
28400627
32.

Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies.

Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR.

Semin Cancer Biol. 2017 Jun;44:153-169. doi: 10.1016/j.semcancer.2017.03.008. Epub 2017 Mar 30. Review.

33.

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.

Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.

Gastroenterology. 2017 Jul;153(1):63-76.e14. doi: 10.1053/j.gastro.2017.03.004. Epub 2017 Mar 9.

PMID:
28286209
34.

Arl13b regulates Shh signaling from both inside and outside the cilium.

Mariani LE, Bijlsma MF, Ivanova AA, Suciu SK, Kahn RA, Caspary T.

Mol Biol Cell. 2016 Sep 28. pii: mbc.E16-03-0189. [Epub ahead of print] Erratum in: Mol Biol Cell. 2017 Apr 1;28(7):996. Ivanova, Anna I [corrected to Ivanova, Anna A].

35.

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21.

Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Małecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT.

Oncotarget. 2016 Oct 11;7(41):66328-66343. doi: 10.18632/oncotarget.11041.

36.

Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity.

van Neerven SM, Tieken M, Vermeulen L, Bijlsma MF.

Mol Cell Oncol. 2015 Dec 2;3(2):e1098791. doi: 10.1080/23723556.2015.1098791. eCollection 2016 Mar. Review.

37.

Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment.

Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, Giovannetti E.

Expert Rev Mol Diagn. 2016 Jul;16(7):733-6. doi: 10.1080/14737159.2016.1175940. Epub 2016 Apr 27. Review.

PMID:
27118062
38.

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.

Ebbing EA, Medema JP, Damhofer H, Meijer SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF, van Laarhoven HW.

Oncotarget. 2016 Mar 1;7(9):10243-54. doi: 10.18632/oncotarget.7200.

39.

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.

Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP.

Nat Genet. 2015 Aug;47(8):911-6. doi: 10.1038/ng.3341. Epub 2015 Jun 22.

40.

Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer.

Klaassen R, Bennink RJ, van Tienhoven G, Bijlsma MF, Besselink MG, van Berge Henegouwen MI, Wilmink JW, Nederveen AJ, Windhorst AD, Hulshof MC, van Laarhoven HW.

Radiother Oncol. 2015 Jul;116(1):94-9. doi: 10.1016/j.radonc.2015.05.009. Epub 2015 Jun 3.

41.

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract.

Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF.

J Transl Med. 2015 Apr 11;13:115. doi: 10.1186/s12967-015-0469-1.

42.

The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.

Bijlsma MF, van Laarhoven HW.

Cancer Metastasis Rev. 2015 Mar;34(1):97-114. doi: 10.1007/s10555-014-9541-1. Review.

PMID:
25566685
43.

Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency.

Damhofer H, Veenstra VL, Tol JA, van Laarhoven HW, Medema JP, Bijlsma MF.

J Cell Sci. 2015 Jan 1;128(1):129-39. doi: 10.1242/jcs.157966. Epub 2014 Oct 29.

44.

Shh-mediated degradation of Hhip allows cell autonomous and non-cell autonomous Shh signalling.

Kwong L, Bijlsma MF, Roelink H.

Nat Commun. 2014 Sep 12;5:4849. doi: 10.1038/ncomms5849.

45.

Ptch2 mediates the Shh response in Ptch1-/- cells.

Alfaro AC, Roberts B, Kwong L, Bijlsma MF, Roelink H.

Development. 2014 Sep;141(17):3331-9. doi: 10.1242/dev.110056. Epub 2014 Aug 1.

46.

Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.

Damhofer H, Medema JP, Veenstra VL, Badea L, Popescu I, Roelink H, Bijlsma MF.

Mol Oncol. 2013 Dec;7(6):1031-42. doi: 10.1016/j.molonc.2013.08.004. Epub 2013 Aug 16.

47.

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.

De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJ, Tuynman JB, Dekker E, Markowetz F, Medema JP, Vermeulen L.

Nat Med. 2013 May;19(5):614-8. doi: 10.1038/nm.3174. Epub 2013 Apr 14.

PMID:
23584090
48.

Hedgehog-stimulated chemotaxis is mediated by smoothened located outside the primary cilium.

Bijlsma MF, Damhofer H, Roelink H.

Sci Signal. 2012 Aug 21;5(238):ra60. doi: 10.1126/scisignal.2002798.

49.

Dichotomy in Hedgehog signaling between human healthy vessel and atherosclerotic plaques.

Queiroz KC, Bijlsma MF, Tio RA, Zeebregts CJ, Dunaeva M, Ferreira CV, Fuhler GM, Kuipers EJ, Alves MM, Rezaee F, Spek CA, Peppelenbosch MP.

Mol Med. 2012 Sep 25;18:1122-7. doi: 10.2119/molmed.2011.00250.

50.

Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors.

Hindriksen S, Bijlsma MF.

Cancers (Basel). 2012 Oct 12;4(4):989-1035. doi: 10.3390/cancers4040989.

Supplemental Content

Loading ...
Support Center